血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2021 ELN共识文件：急性髓性白血病的可测量残留病（更新版）

2021-11-01 欧洲白血病网 Blood

急性髓性白血病

2021年11月，欧洲白血病网(ELN)更新发布了急性髓性白血病的可测量残留病专家共识文件。可测量残留病（MRD）是急性髓性白血病（AML）的重要生物标志物，主要用于预后、预测、监测以及疗效评估。

中文标题：

2021 ELN共识文件：急性髓性白血病的可测量残留病（更新版）

英文标题：

2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document

发布机构：

欧洲白血病网

发布日期：

2021-11-01

简要介绍：

2021年11月，欧洲白血病网(ELN)更新发布了急性髓性白血病的可测量残留病专家共识文件。可测量残留病（MRD）是急性髓性白血病（AML）的重要生物标志物，主要用于预后、预测、监测以及疗效评估。ELN工作组基于该领域额进展对2018年MRD建议进行了更新。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ELN共识文件：急性髓性白血病的可测量残留病（更新版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3e41c1c0022a961a, title=2021 ELN共识文件：急性髓性白血病的可测量残留病（更新版）, enTitle=2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document, guiderFrom=Blood, authorId=0, author=, summary=2021年11月，欧洲白血病网(ELN)更新发布了急性髓性白血病的可测量残留病专家共识文件。可测量残留病（MRD）是急性髓性白血病（AML）的重要生物标志物，主要用于预后、预测、监测以及疗效评估。, cover=https://img.medsci.cn/2021112/1635818222291_5579292.jpg, journalId=0, articlesId=null, associationId=148, associationName=欧洲白血病网, associationIntro=欧洲白血病网由欧盟资助，包含白血病相关的医生，科学家和白血病患者。其旨在提高欧洲白血病的治疗及知识传播，促进医生及患者教育。, copyright=0, guiderPublishedTime=Mon Nov 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年11月，欧洲白血病网(ELN)更新发布了急性髓性白血病的可测量残留病专家共识文件。可测量残留病（MRD）是急性髓性白血病（AML）的重要生物标志物，主要用于预后、预测、监测以及疗效评估。ELN工作组基于该领域额进展对2018年MRD建议进行了更新。</span></p>, tagList=[TagDto(tagId=743, tagName=急性髓性白血病)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=743, guiderKeyword=急性髓性白血病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3586, appHits=140, showAppHits=0, pcHits=1068, showPcHits=3446, likes=1, shares=12, comments=9, approvalStatus=1, publishedTime=Tue Nov 02 10:25:19 CST 2021, publishedTimeString=2021-11-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Nov 02 10:01:07 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 07:09:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ELN共识文件：急性髓性白血病的可测量残留病（更新版）.pdf)])
2021 ELN共识文件：急性髓性白血病的可测量残留病（更新版）.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186510, encodeId=193b11865101d, content=更新好快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c45d5516864, createdName=康医生, createdTime=Thu Jan 20 17:37:09 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184531, encodeId=6afb118453108, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ddc5729753, createdName=ms6000001985805349, createdTime=Sat Jan 15 11:00:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079655, encodeId=01b910e96558f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b8c6396431, createdName=ms7000001558652221, createdTime=Mon Dec 13 19:18:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073641, encodeId=f78710e364194, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200825/7604133fa4724e12bf9b0b771bb0480f/066d4f0aa17148c59fb04649d7905189.jpg, createdBy=11823001903, createdName=积极向上的青年, createdTime=Wed Nov 24 21:25:52 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071948, encodeId=c14510e194867, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b95700210, createdName=ms8000000176189459, createdTime=Sat Nov 20 01:57:49 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2022-01-20 康医生

    更新好快

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186510, encodeId=193b11865101d, content=更新好快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c45d5516864, createdName=康医生, createdTime=Thu Jan 20 17:37:09 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184531, encodeId=6afb118453108, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ddc5729753, createdName=ms6000001985805349, createdTime=Sat Jan 15 11:00:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079655, encodeId=01b910e96558f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b8c6396431, createdName=ms7000001558652221, createdTime=Mon Dec 13 19:18:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073641, encodeId=f78710e364194, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200825/7604133fa4724e12bf9b0b771bb0480f/066d4f0aa17148c59fb04649d7905189.jpg, createdBy=11823001903, createdName=积极向上的青年, createdTime=Wed Nov 24 21:25:52 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071948, encodeId=c14510e194867, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b95700210, createdName=ms8000000176189459, createdTime=Sat Nov 20 01:57:49 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2022-01-15 ms6000001985805349

    非常好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186510, encodeId=193b11865101d, content=更新好快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c45d5516864, createdName=康医生, createdTime=Thu Jan 20 17:37:09 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184531, encodeId=6afb118453108, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ddc5729753, createdName=ms6000001985805349, createdTime=Sat Jan 15 11:00:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079655, encodeId=01b910e96558f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b8c6396431, createdName=ms7000001558652221, createdTime=Mon Dec 13 19:18:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073641, encodeId=f78710e364194, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200825/7604133fa4724e12bf9b0b771bb0480f/066d4f0aa17148c59fb04649d7905189.jpg, createdBy=11823001903, createdName=积极向上的青年, createdTime=Wed Nov 24 21:25:52 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071948, encodeId=c14510e194867, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b95700210, createdName=ms8000000176189459, createdTime=Sat Nov 20 01:57:49 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-12-13 ms7000001558652221

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186510, encodeId=193b11865101d, content=更新好快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c45d5516864, createdName=康医生, createdTime=Thu Jan 20 17:37:09 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184531, encodeId=6afb118453108, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ddc5729753, createdName=ms6000001985805349, createdTime=Sat Jan 15 11:00:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079655, encodeId=01b910e96558f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b8c6396431, createdName=ms7000001558652221, createdTime=Mon Dec 13 19:18:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073641, encodeId=f78710e364194, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200825/7604133fa4724e12bf9b0b771bb0480f/066d4f0aa17148c59fb04649d7905189.jpg, createdBy=11823001903, createdName=积极向上的青年, createdTime=Wed Nov 24 21:25:52 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071948, encodeId=c14510e194867, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b95700210, createdName=ms8000000176189459, createdTime=Sat Nov 20 01:57:49 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-24 积极向上的青年

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186510, encodeId=193b11865101d, content=更新好快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c45d5516864, createdName=康医生, createdTime=Thu Jan 20 17:37:09 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184531, encodeId=6afb118453108, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ddc5729753, createdName=ms6000001985805349, createdTime=Sat Jan 15 11:00:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079655, encodeId=01b910e96558f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b8c6396431, createdName=ms7000001558652221, createdTime=Mon Dec 13 19:18:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073641, encodeId=f78710e364194, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200825/7604133fa4724e12bf9b0b771bb0480f/066d4f0aa17148c59fb04649d7905189.jpg, createdBy=11823001903, createdName=积极向上的青年, createdTime=Wed Nov 24 21:25:52 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071948, encodeId=c14510e194867, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b95700210, createdName=ms8000000176189459, createdTime=Sat Nov 20 01:57:49 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-20 ms8000000176189459

    学习学习

    0

相关指南

2020 ASH指南：新诊断老年急性髓性白血病的治疗

美国血液病学会(ASH,American Society of Hematology) · 2020-08-09

拓展阅读

2015 BCSH指南：妊娠期急性髓性白血病的诊断和管理

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2015-06-17

2020 ASH指南：新诊断老年急性髓性白血病的治疗

美国血液病学会(ASH,American Society of Hematology) · 2020-08-09

FDA 行业指南：急性髓性白血病的开发治疗药物和生物制品

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2022-10-17

2023 SIOG建议：70岁及以上急性髓性白血病患者的治疗

国际老年肿瘤学会(SIOG,International Society of Geriatric Oncology) · 2023-09-21

2023 GFCH指南：细胞遗传学在急性髓性白血病和组织细胞/树突状细胞肿瘤管理中的应用

暂未更新 · 2023-12-29

2023 JSH实践指南：血液恶性肿瘤—Ⅰ.白血病-1.急性髓性白血病

暂未更新 · 2024-03-14